List of Excipients in Branded Drug CICLODAN

« Back to Dashboard

Generic Drugs Containing CICLODAN

Company	Ingredient	NDC	Excipient
Medimetriks Pharmaceuticals Inc	ciclopirox	43538-500	BUTYL ESTER OF METHYL VINYL ETHER/MALEIC ANHYDRIDE COPOLYMER
Medimetriks Pharmaceuticals Inc	ciclopirox	43538-500	ETHYL ACETATE
Medimetriks Pharmaceuticals Inc	ciclopirox	43538-500	ISOPROPYL ALCOHOL

What are the Most Frequently-Used Excipients in CICLODAN?

# Of NDCs	Excipient
1	BUTYL ESTER OF METHYL VINYL ETHER/MALEIC ANHYDRIDE COPOLYMER
1	ETHYL ACETATE
1	ISOPROPYL ALCOHOL

Last updated: October 5, 2026

ecutive summary: Ciclodan is a topical ciclopirox product used for superficial fungal infections. Its commercial value depends more on formulation performance, patient adherence, manufacturing cost, and channel access than on active-ingredient exclusivity. The strongest opportunities are differentiated topical formats, low-irritation excipient systems, improved nail delivery, preservative optimization, and combination products that remain within accepted regulatory pathways. Ciclodan should be evaluated by dosage form because cream, gel, lotion, shampoo, and nail-lacquer products have different excipient, regulatory, and patent profiles.

Ciclodan Excipient Strategy and Commercial Opportunities for Ciclopirox Topical Products

What is Ciclodan and which active ingredient does it contain?

Ciclodan is a topical antifungal brand associated with ciclopirox or ciclopirox olamine. Ciclopirox is a hydroxypyridone antifungal used against dermatophytes, yeasts, and certain molds. Ciclopirox olamine is the salt form commonly used in creams, gels, lotions, and shampoos. Ciclopirox is also used in nail-lacquer products at higher concentrations.

The commercial and formulation analysis should separate the following product categories:

Product category	Typical active form	Typical strength	Primary use	Main excipient challenge
Cream	Ciclopirox olamine	0.77%	Tinea, candidiasis, seborrheic dermatitis	Solubilization, skin feel, preservative control
Gel or lotion	Ciclopirox olamine	0.77%	Intertriginous and hairy areas	Drying time, spreadability, residue
Shampoo	Ciclopirox olamine	1%	Seborrheic dermatitis	Foam, rinseability, scalp tolerability
Nail lacquer	Ciclopirox	8%	Onychomycosis	Film formation, nail penetration, removal burden

Ciclodan’s addressable market is therefore not a single product market. It includes dermatology prescriptions, generic topical antifungals, scalp-care products, and prescription nail treatments.

What excipients are used in Ciclodan-type formulations?

The exact composition depends on the dosage form and marketed product. Public product labels and inactive-ingredient databases should be used to confirm the excipient profile for each NDC or marketed presentation before making a formulation, equivalence, or freedom-to-operate decision.[1,2]

Cream and emulsion systems

A ciclopirox olamine cream generally requires:

• An oil phase for emollience and occlusivity.
• A surfactant or emulsifier system.
• A humectant such as propylene glycol or glycerin.
• A viscosity modifier.
• A preservative system.
• Purified water.
• pH adjustment where needed.

The commercial target is a stable oil-in-water cream that spreads quickly, does not sting compromised skin, and leaves limited residue. The formulation must maintain drug uniformity during storage and support release from the vehicle after application.

Suitable excipient categories include:

Function	Candidate excipient classes	Commercial objective
Humectancy and cosolvency	Propylene glycol, glycerin, polyethylene glycol	Improve hydration and drug distribution
Emollience	Medium-chain triglycerides, fatty alcohols, esters	Improve skin feel and reduce dryness
Emulsification	Nonionic surfactants, glyceryl stearates, polysorbates	Maintain physical stability
Rheology	Carbomers, acrylates, cellulose derivatives	Control spread, residence time, and phase stability
Preservation	Phenoxyethanol, parabens, organic acids, benzoate systems	Control microbial growth
pH control	Citrate, phosphate, or other buffers	Support stability and tolerability

The principal formulation risk is excessive reliance on propylene glycol or surfactants. These ingredients can improve solubilization but may increase stinging, erythema, or irritancy in inflamed skin. A lower-irritation vehicle can support premium positioning and improve adherence, particularly for infections involving skin folds or fissured skin.

Gel and lotion systems

Gels and lotions can target patients who reject creams because of greasiness. A gel may dry faster and work better on hairy areas, while a lotion can provide broader coverage with less residue.

Priority development attributes include:

1. Rapid drying without excessive alcohol-related irritation.
2. Uniform drug distribution during filling and storage.
3. Low tack after application.
4. Adequate residence time on the affected area.
5. Compatibility with pumps, tubes, and metered dispensers.

Alcohol-based systems can improve drying time and microbial robustness but may produce burning on damaged skin. Water-rich gels may improve tolerability but require stronger preservation and tighter control of viscosity and microbial quality.

A differentiated Ciclodan gel could compete through a low-residue claim, a non-greasy sensory profile, or a dispensing format that reduces contamination from repeated tube handling. These attributes are commercially relevant even when the active ingredient is generic.

Shampoo systems

Ciclopirox olamine shampoo requires a surfactant system that balances cleansing, foam, rinseability, and scalp tolerability. Excessive detergency can worsen dryness and undermine repeat use. The formulation also needs adequate viscosity and suspension or solubilization control.

Potential excipient strategies include:

• Mild amphoteric and nonionic surfactants.
• Reduced sulfate loading.
• Conditioning polymers to reduce post-wash roughness.
• Humectants for scalp comfort.
• Chelating agents to improve preservative performance.
• Fragrance-free or low-fragrance versions for sensitive users.

A shampoo product may have stronger commercial differentiation potential than a conventional cream because patient experience, packaging, fragrance, foam, and hair feel influence repeat purchase.

What excipient strategy is best for Ciclodan cream?

A commercially competitive Ciclodan cream should use a low-irritation, cosmetically acceptable oil-in-water system with controlled viscosity and limited residue. The development program should prioritize:

• Consistent drug release across the shelf life.
• No visible phase separation.
• Stable viscosity under accelerated conditions.
• Low sting on compromised skin.
• Compatibility with aluminum, laminate, and polymer tubes.
• Preservative efficacy after repeated opening.
• Efficient manufacture without high-shear processing requirements.

The most defensible product differentiation would come from the complete vehicle rather than any individual inactive ingredient. A single excipient substitution is rarely sufficient to create a durable barrier. A proprietary combination of solubilizer, emulsion architecture, rheology modifier, and packaging system has greater potential for formulation patenting and regulatory differentiation.

Which excipients can support a lower-irritation formulation?

A lower-irritation strategy would generally reduce unnecessary fragrance, minimize high levels of volatile alcohol, control surfactant concentration, and avoid excessive solvent loading. The formulation should be screened against:

• Propylene glycol irritation.
• Preservative sensitivity.
• Surfactant-induced barrier disruption.
• pH-related stinging.
• Fragrance and essential-oil sensitization.

The final excipient selection must be supported by skin compatibility testing, preservative challenge testing, stability data, and comparative drug-release testing. The FDA Inactive Ingredient Database can identify previously used excipients and route-specific precedent, but it does not establish that a particular concentration or combination is acceptable for every formulation.[2]

What excipient strategy is best for Ciclodan nail lacquer?

The nail-lacquer opportunity is technically more demanding. Ciclopirox 8% lacquer products use a film-forming vehicle designed to retain the active on the nail plate and support penetration into infected keratin. Penlac labeling identifies a vehicle containing ethyl acetate, isopropyl alcohol, and a vinyl acetate-based copolymer.[3]

A next-generation lacquer could target:

• Faster drying.
• Lower odor.
• Reduced brittleness.
• Improved nail penetration.
• Easier removal.
• Fewer required removal steps.
• Better adherence to the nail plate.
• Compatibility with cosmetic nail products.

Potential excipient approaches include alternative film-formers, plasticizers, co-solvent systems, water-compatible polymers, and nail-penetration enhancers. Each change creates tradeoffs. A stronger film may improve retention but increase removal burden. Higher solvent content may improve drying but increase odor and nail brittleness. More hydrophilic polymers may improve removal but reduce residence time.

The most commercially attractive lacquer platform would combine once-daily use with a thinner, faster-drying film and simplified removal. The clinical value proposition must be supported by comparative adherence and efficacy data because formulation improvements alone do not guarantee superior mycological outcomes.

What formulation patents could protect a Ciclodan product?

The active ingredient and basic topical uses are mature. Patent value is more likely to arise from formulation and delivery claims than from ciclopirox itself.

Potentially protectable subject matter includes:

• Specific solvent and cosolvent ratios.
• Film-forming polymer combinations.
• Low-irritation preservative systems.
• Controlled-release topical vehicles.
• Nanoemulsion or microemulsion systems.
• Improved nail penetration.
• Reduced removal requirements.
• Stable high-concentration ciclopirox formulations.
• Unit-dose or metered-dose packaging.
• Combination products containing ciclopirox and another active.
• Manufacturing processes that produce a defined particle-size distribution or polymorphic form.

A patent must provide more than a routine substitution of one pharmaceutically acceptable excipient for another. Stronger claims would link the composition to a measurable technical effect, such as improved nail penetration, longer residence time, lower irritation, enhanced stability, or improved release.

A freedom-to-operate review should cover U.S., European, Japanese, Chinese, and major emerging-market filings. Patent families for topical formulations can have narrow geographic coverage and different expiration dates even when they share a common priority filing.

What is the FDA regulatory status of Ciclodan?

Ciclopirox topical products are prescription dermatology products in the United States. Regulatory status varies by dosage form and product-specific application. Cream, gel, lotion, shampoo, and lacquer products may be approved under different New Drug Applications or abbreviated pathways.

For a proposed generic or line extension, the regulatory route depends on the reference product:

• A conventional topical generic may require an ANDA if the product can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA framework.
• A product with a materially different formulation, delivery system, or clinical claim may require a 505(b)(2) application.
• A novel combination or indication may require additional clinical or pharmacodynamic evidence.

FDA topical-product guidance has increased the importance of comparative quality attributes, including formulation characterization, product performance, and, where applicable, in vitro release or permeation data.[4]

What is the Orange Book status of Ciclodan?

The Orange Book lists FDA-approved drug products and relevant patent and exclusivity information. The status of a particular Ciclodan product must be checked by product name, active ingredient, dosage form, strength, and application number because brand names and NDC presentations do not always map to a single regulatory record.[5]

For mature ciclopirox products, the main commercial barriers are usually:

• Reference-product sourcing.
• Formulation sameness.
• Product-specific bioequivalence requirements.
• Manufacturing scale-up.
• State substitution rules.
• Contracting and reimbursement.
• Retail and dermatology-channel access.

The absence of a prominent active-ingredient patent does not eliminate regulatory risk. A listed formulation or method-of-use patent can still create Paragraph IV exposure if it remains relevant to the reference product.

When does Ciclodan lose exclusivity?

Ciclodan’s exclusivity position cannot be assigned to the brand name alone. Exclusivity depends on the specific FDA application, dosage form, approval date, listed patents, pediatric exclusivity, and any regulatory exclusivity attached to the reference product.

Ciclopirox topical products are mature enough that the principal threat is generic competition rather than biosimilar competition. Biosimilar pathways do not apply because ciclopirox is a small-molecule drug, not a biologic. A generic entrant could target cream, gel, lotion, shampoo, or lacquer products separately, subject to the applicable reference product and FDA requirements.

Which companies could challenge Ciclodan or compete with it?

Competition is likely to come from three groups:

1. Generic dermatology manufacturers supplying ciclopirox creams, gels, lotions, shampoos, or solutions.
2. Branded antifungal companies selling alternative actives such as ketoconazole, terbinafine, efinaconazole, or tavaborole.
3. Specialty dermatology companies developing improved delivery systems or combination products.

For nail disease, ciclopirox competes with efinaconazole and tavaborole products. For seborrheic dermatitis, it competes with ketoconazole shampoo, selenium sulfide, zinc pyrithione where available, and corticosteroid-containing regimens. For tinea infections, it competes with terbinafine, azoles, and other topical antifungals.

Ciclodan’s commercial advantage is likely to be price and established clinical familiarity. Its disadvantages include the adherence burden associated with some topical regimens and, for nail lacquer, lower convenience relative to newer products.

What commercial opportunities exist for Ciclodan?

The strongest opportunities are:

1. Premium generic cream

A cream with improved skin feel, low residue, low fragrance, and reduced irritation could command better formulary acceptance or cash-pay pricing than a basic generic.

2. Low-residue gel

A fast-drying gel could target athletes, patients with hairy skin, and users who avoid occlusive creams.

3. Sensitive-scalp shampoo

A mild, fragrance-free shampoo could compete for patients with recurrent seborrheic dermatitis who discontinue products because of dryness or irritation.

4. Improved nail lacquer

A faster-drying, easier-to-remove lacquer could address the principal adherence weakness of traditional nail products.

5. Combination therapy

Ciclopirox could be evaluated with keratolytic, anti-inflammatory, or barrier-supporting components. Combination claims would require careful regulatory and safety analysis. Corticosteroid combinations may improve short-term inflammation but increase regulatory and labeling complexity.

6. Contract manufacturing and private label

A manufacturer with validated topical capabilities could supply dermatology brands, telehealth companies, pharmacy chains, and international distributors. The value proposition would depend on batch consistency, preservative robustness, packaging flexibility, and reliable regulatory documentation.

How strong is the patent estate for Ciclodan?

The likely estate is stronger around product execution than around the core active ingredient. Mature ciclopirox chemistry creates limited opportunity for broad composition-of-matter protection. The most defensible assets would be:

• A clinically differentiated formulation.
• A measurable delivery improvement.
• A manufacturing process that produces a superior critical quality attribute.
• A proprietary package and dispensing system.
• A combination product supported by clinical evidence.

A formulation patent with only broad excipient language would face validity and obviousness pressure. Claims tied to unexpected performance, comparative data, and defined composition ranges are more commercially useful.

What litigation and Paragraph IV risks affect Ciclodan?

Potential litigation would most likely involve:

• A Paragraph IV challenge to a listed formulation patent.
• A dispute over pharmaceutical equivalence.
• A method-of-use patent covering a particular indication.
• Trade dress or trademark claims involving the Ciclodan name.
• Manufacturing or supply agreements.
• Patent disputes over nail-lacquer polymers or delivery systems.

The litigation risk is product-specific. A generic cream applicant may not face the same patent landscape as a nail-lacquer applicant. Paragraph IV exposure is also shaped by the patents listed for the selected reference product, not by the broad ciclopirox market.

Key takeaways

• Ciclodan is a ciclopirox-based topical antifungal brand whose commercial potential depends on dosage form.
• Cream and gel opportunities center on tolerability, spreadability, residue, and low-cost manufacturing.
• Shampoo opportunities center on mild surfactants, scalp comfort, foam, and repeat-use adherence.
• Nail-lacquer opportunities center on film formation, nail penetration, drying time, and simplified removal.
• Formulation patents are more promising than broad active-ingredient patents.
• Biosimilar risk is not relevant because ciclopirox is a small molecule.
• FDA, Orange Book, Paragraph IV, and litigation analysis must be performed by specific dosage form and reference application.
• The best commercial strategy is a differentiated vehicle supported by comparative performance data, not a routine excipient substitution.

FAQs about Ciclodan excipient and commercial strategy

Can propylene glycol be removed from a Ciclodan cream?

Yes, but removing it may affect ciclopirox solubilization, drug release, viscosity, and preservative performance. A substitute system would require comparative stability and release testing.

Is a ciclopirox nail lacquer eligible for a 505(b)(2) application?

It may be, depending on the reference product, formulation differences, and the data required to support the proposed product. The regulatory route must be assessed against the selected reference drug.

Which Ciclodan dosage form has the strongest differentiation potential?

The nail lacquer has the greatest technical differentiation potential, while the cream and gel have the clearest path to cost-efficient generic or premium-generic commercialization.

Are excipient combinations patentable in a Ciclodan product?

Yes. Patentability is stronger when the combination is tied to an unexpected technical effect, defined composition ranges, or improved clinical or product performance.

Does Ciclodan compete directly with efinaconazole?

Ciclopirox and efinaconazole both compete in topical onychomycosis, but their formulations, treatment regimens, clinical evidence, pricing, and adherence characteristics differ.

References

1. DailyMed. (n.d.). Ciclopirox olamine topical products and Ciclodan prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Penlac ciclopirox topical solution 8% prescribing information. Drugs@FDA.

4. U.S. Food and Drug Administration. (2022). Acyclovir topical cream and ointment product-specific guidance; topical dermatological drug development guidance. FDA.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm